News

Medical cannabis programs have moved from the margins to the mainstream in less than a decade, reshaping not just policy, but the lived experience of millions of patients. Yet, as adoption scales, the friction between oversight and autonomy compounds: Drug testing—once a bolt-on compliance mechanism—now sits at the heart of governance for patient safety, eligibility, […]

Urine drug testing is rapidly becoming a structural fixture in the landscape of medical cannabis use, especially for patients enrolled in Montana’s medical cannabis program. But for all its routine velocity—employers, healthcare providers, and legal authorities now request these tests with increasing frequency—the process is fraught with nuance and potential for compounding friction. Patients are […]

Urine drug testing has become a fixture of modern compliance—woven into medical protocols, employment screens, and legal oversight. Its velocity is only compounding: According to Quest Diagnostics’ 2023 Drug Testing Index, more than 10 million workplace drug tests are performed annually in the United States alone, with similar numbers reflected in clinical settings. The goal […]

Urine drug testing has become a mainstay within medical cannabis programs across the United States. For patients, the process is rarely just a routine clinical formality—it can also present a compound set of privacy concerns that often go unaddressed in the rush to comply with regulations or workplace mandates. You may be asked to provide […]

Urine drug testing is a fixture in both clinical medicine and workplace compliance. It’s a tool deployed to manage risk—screening for substance use before surgery, hiring, or as part of ongoing employment. But in the rapid velocity of policy updates and shifting legal frameworks—especially around medical cannabis—confusion compounds. Patients, employers, and even clinicians often find […]

Drug testing in medical settings is not new—workplace safety programs, pain management clinics, and addiction treatment centers have relied on biological sampling for decades to triage patient needs and manage risk. But in the rapidly evolving landscape of medical cannabis, urine drug testing has taken on a new velocity and visibility. For both patients and […]

Drug testing didn’t start as a mainstream business risk, but its currency has only compounded over the past decade. Today, employers are scrutinized for compliance lapses, courts demand forensic accuracy, and healthcare providers face complex triage when substance use is suspected. The friction is real: One missed detail in a test can evaporate legal protections […]

Medical cannabis programs have evolved at a velocity that few in healthcare anticipated. Once restricted to a handful of jurisdictions, these programs now touch millions of patients in over 40 U.S. states, as well as dozens of countries abroad. This rapid expansion amplifies not only patient access but also the compounding responsibility of compliance—for both […]

Medical cannabis programs have proliferated at a striking velocity over the past decade, moving from fringe policy experiments to mainstream components of national healthcare systems. Canada, Germany, Israel, and over half of U.S. states now operate some form of regulated medical cannabis access. But in many cases, program expansion has outpaced the creation of robust […]

Medical cannabis programs have proliferated at a velocity few predicted a decade ago—38 U.S. states as of 2024, millions of registered patients, and a regulatory landscape that shifts almost quarterly. But for all the compounding interest and capital, the core value proposition remains unchanged: deliver therapeutic benefit without introducing new risks. This is what leads […]